Focused On-demand Library for Interleukin-3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P08700

UPID:

IL3_HUMAN

Alternative names:

Hematopoietic growth factor; Mast cell growth factor; Multipotential colony-stimulating factor; P-cell-stimulating factor

Alternative UPACC:

P08700; Q6GS87

Background:

Interleukin-3, known as a Hematopoietic growth factor, plays a pivotal role in the regulation of hematopoietic progenitor cells differentiation and lineage restriction. It is secreted by T-lymphocytes, mast cells, and osteoblastic cells, influencing various cell types including basophils, eosinophils, and monocytes. Beyond hematopoiesis, Interleukin-3 is crucial for neural cell proliferation and bone homeostasis, inhibiting osteoclast differentiation through NF-kappa-B pathway modulation.

Therapeutic significance:

Understanding the role of Interleukin-3 could open doors to potential therapeutic strategies. Its involvement in cell proliferation, survival, and differentiation highlights its potential as a target for treating hematopoietic disorders and bone diseases.